Back
RiverNorth/DoubleLine Strategic opportunity fund Vs. Oruka Therapeutics, Inc. Industry Stock Comparison
Sell
36
OPP
RiverNorth/DoubleLine Strategic opportunity fund
Last Price:
$7.64
Seasonality Move:
1.5%
Buy
100
ORKA
Oruka Therapeutics, Inc.
Last Price:
$53.39
Seasonality Move:
5.42%
Sell
36
RiverNorth/DoubleLine Strategic opportunity fund (OPP)
is a Sell
Is RiverNorth/DoubleLine Strategic opportunity fund a Buy, Sell or Hold?
-
The current RiverNorth/DoubleLine Strategic opportunity fund [OPP] share price is $7.68. The Score for OPP is 36, which is 28% below its historic median score of 50, and infers higher risk than normal.
-
OPP is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Buy
100
Oruka Therapeutics, Inc. (ORKA)
is a Buy
Is Oruka Therapeutics, Inc. a Buy, Sell or Hold?
-
The current Oruka Therapeutics, Inc. [ORKA] share price is $53.31. The Score for ORKA is 100, which is 100% above its historic median score of 50, and infers lower risk than normal.
-
ORKA is currently trading in the 90-100% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing an extreme reading that indicates risk levels may be considerably lower than normal.
OPP Stock Price Chart
What is RiverNorth/DoubleLine Strategic opportunity fund's stock price today?
-
The RiverNorth/DoubleLine Strategic opportunity fund share price today is $7.68The current trend is relatively stagnant and OPP is experiencing slight buying pressure.
ORKA Stock Price Chart
What is Oruka Therapeutics, Inc.'s stock price today?
-
The Oruka Therapeutics, Inc. share price today is $53.31Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ORKA is experiencing buying pressure, which is a positive indicator for future bullish movement.
OPP Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.05 | Sell |
| Relative Strength Index (14 RSI): | 50.31 | Buy |
| Chaikin Money Flow: | 31615 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (7.55 - 7.79) | Buy |
| Bollinger Bands (100): | (7.72 - 8) | Sell |
ORKA Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 4.1 | Buy |
| Relative Strength Index (14 RSI): | 77.59 | Buy |
| Chaikin Money Flow: | 1458349 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (33.68 - 45.6) | Buy |
| Bollinger Bands (100): | (27.9 - 38.44) | Buy |
OPP Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 7.6 | Buy |
| 20-day SMA: | 7.63 | Buy |
| 50-day SMA: | 7.78 | Sell |
| 200-day SMA: | 8.18 | Sell |
| 8-day EMA: | 7.62 | Buy |
| 20-day EMA: | 7.65 | Buy |
| 50-day EMA: | 7.75 | Sell |
| 200-day EMA: | 8.07 | Sell |
ORKA Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 46.5 | Buy |
| 20-day SMA: | 41.09 | Buy |
| 50-day SMA: | 36.64 | Buy |
| 200-day SMA: | 25.3 | Buy |
| 8-day EMA: | 47.34 | Buy |
| 20-day EMA: | 42.69 | Buy |
| 50-day EMA: | 37.82 | Buy |
| 200-day EMA: | 28.4 | Buy |
RiverNorth/DoubleLine Strategic opportunity fund Earnings Growth & OPP Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Oruka Therapeutics, Inc. Earnings Growth & ORKA Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.05 per share, an increase next quarter of $0.05 per share, a decrease this year of $0.14 per share, and a decrease next year of $0.31 per share.
RiverNorth/DoubleLine Strategic opportunity fund Technical Analysis
| Mar 20 | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 30 | Mar 31 | Apr 1 | Apr 2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | Apr | |||||||||
| 20 | 23 | 24 | 25 | 26 | 27 | 30 | 31 | 01 | 02 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Oruka Therapeutics, Inc. Technical Analysis
| Mar 20 | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 30 | Mar 31 | Apr 1 | Apr 2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | Apr | |||||||||
| 20 | 23 | 24 | 25 | 26 | 27 | 30 | 31 | 01 | 02 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||